Assertio Divests Sympazan® and Other Products to Cosette Pharma
Summary
Assertio Holdings, Inc. has announced the divestiture of its Sympazan® product and additional products to Cosette Pharmaceuticals. This transaction is highly significant as it occurs shortly after Assertio agreed to be acquired by Garda Therapeutics, a material event reported earlier today. The sale of these assets alters Assertio's product portfolio, which is crucial for a company undergoing a full acquisition and could influence the final valuation or terms of the Garda deal. Traders will be closely monitoring for financial details of this divestiture and any further implications for the pending acquisition.
At the time of this announcement, ASRT was trading at $18.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $118.7M. The 52-week trading range was $7.71 to $20.45. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.